{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T18:09:10Z","timestamp":1792346950373,"version":"4.4.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T00:00:00Z","timestamp":1622764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T00:00:00Z","timestamp":1622764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Shire International GmbH, Zug, Switzerland, a member of the Takeda group of companies, and Shionogi & Co., Ltd., Osaka, Japan"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s40120-021-00249-0","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T16:03:02Z","timestamp":1622822582000},"page":"499-522","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Efficacy and Safety of Medication for Attention-Deficit Hyperactivity Disorder in Children and Adolescents with Common Comorbidities: A Systematic Review"],"prefix":"10.1007","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3434-6280","authenticated-orcid":false,"given":"Noa","family":"Tsujii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahide","family":"Usami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1879-3603","authenticated-orcid":false,"given":"Noriyuki","family":"Naya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3685-0763","authenticated-orcid":false,"given":"Toshinaga","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Mishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Horie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junzo","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,4]]},"reference":[{"issue":"1","key":"249_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12402-014-0142-1","volume":"7","author":"CM Jensen","year":"2015","unstructured":"Jensen CM, Steinhausen HC. Comorbid mental disorders in children and adolescents with attention-deficit\/hyperactivity disorder in a large nationwide study. Atten Defic Hyperact Disord. 2015;7(1):27\u201338.","journal-title":"Atten Defic Hyperact Disord"},{"issue":"12","key":"249_CR2","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1007\/s00787-017-1005-z","volume":"26","author":"L Reale","year":"2017","unstructured":"Reale L, Bartoli B, Cartabia M, et al. Comorbidity prevalence and treatment outcome in children and adolescents with ADHD. Eur Child Adolesc Psychiatry. 2017;26(12):1443\u201357.","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"249_CR3","doi-asserted-by":"publisher","first-page":"373","DOI":"10.2147\/NDT.S121391","volume":"13","author":"M Fridman","year":"2017","unstructured":"Fridman M, Banaschewski T, Sikirica V, Quintero J, Erder MH, Chen KS. Factors associated with caregiver burden among pharmacotherapy-treated children\/adolescents with ADHD in the Caregiver Perspective on Pediatric ADHD survey in Europe. Neuropsychiatr Dis Treat. 2017;13:373\u201386.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"5","key":"249_CR4","doi-asserted-by":"publisher","first-page":"e541","DOI":"10.1542\/peds.2004-0844","volume":"114","author":"AF Klassen","year":"2004","unstructured":"Klassen AF, Miller A, Fine S. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit\/hyperactivity disorder. Pediatrics. 2004;114(5):e541\u20137.","journal-title":"Pediatrics"},{"key":"249_CR5","doi-asserted-by":"crossref","unstructured":"Sparrow EP, Erhardt D. Essentials of ADHD assessment for children and adolescents. In: Kaufman AS, Kaufman NL, series editors. Essentials of psychological assessment. Hoboken: Wiley; 2014.","DOI":"10.1002\/9781394260508"},{"issue":"11","key":"249_CR6","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1056\/NEJMra1917069","volume":"383","author":"M Cortese","year":"2020","unstructured":"Cortese M. Pharmacologic treatment of attention deficit\u2013hyperactivity disorder. N Engl J Med. 2020;383(11):1050\u20136.","journal-title":"N Engl J Med"},{"key":"249_CR7","unstructured":"Canadian ADHD Resource Alliance (CADDRA). Canadian ADHD practice guidelines, 4.1 Edition. Toronto: CADDRA; 2020. https:\/\/www.caddra.ca\/canadian-adhd-practice-guidelines\/. Accessed 14 Mar 2021."},{"key":"249_CR8","volume-title":"Diagnosis and treatment guidelines on attention-deficit hyperactivity disorder (ADHD)","author":"Committee on Diagnosis and Treatment Guidelines of ADHD","year":"2016","unstructured":"Committee on Diagnosis and Treatment Guidelines of ADHD. Diagnosis and treatment guidelines on attention-deficit hyperactivity disorder (ADHD). 4th ed. Tokyo: Jiho; 2016.","edition":"4"},{"key":"249_CR9","unstructured":"National Institute for Care and Health Excellence. Attention deficit hyperactivity disorder: diagnosis and management. NICE guideline [NG87]. Published March 2018, last updated September 2019. https:\/\/www.nice.org.uk\/guidance\/ng87\/chapter\/Recommendations. Accessed 3 Mar 2020."},{"issue":"3","key":"249_CR10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1177\/0269881113519509","volume":"28","author":"B Bolea-Alama\u00f1ac","year":"2014","unstructured":"Bolea-Alama\u00f1ac B, Nutt DJ, Adamou M, et al. Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28(3):179\u2013203.","journal-title":"J Psychopharmacol"},{"issue":"4","key":"249_CR11","doi-asserted-by":"publisher","first-page":"e20192528","DOI":"10.1542\/peds.2019-2528","volume":"144","author":"ML Wolraich","year":"2019","unstructured":"Wolraich ML, Hagan JF Jr, Allan C, et al. Subcommittee on children and adolescents with attention-deficit\/hyperactive disorder. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit\/hyperactivity disorder in children and adolescents. Pediatrics. 2019;144(4):e20192528.","journal-title":"Pediatrics"},{"issue":"7","key":"249_CR12","doi-asserted-by":"publisher","first-page":"e0180355","DOI":"10.1371\/journal.pone.0180355","volume":"12","author":"F Catal\u00e1-L\u00f3pez","year":"2017","unstructured":"Catal\u00e1-L\u00f3pez F, Hutton B, N\u00fa\u00f1ez-Beltr\u00e1n A, et al. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: a systematic review with network meta-analyses of randomised trials. PLoS ONE. 2017;12(7):e0180355.","journal-title":"PLoS ONE"},{"issue":"9","key":"249_CR13","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S2215-0366(18)30269-4","volume":"5","author":"S Cortese","year":"2018","unstructured":"Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727\u201338.","journal-title":"Lancet Psychiatry"},{"issue":"9","key":"249_CR14","doi-asserted-by":"publisher","first-page":"6655","DOI":"10.1007\/s12035-016-0179-6","volume":"54","author":"Y Li","year":"2017","unstructured":"Li Y, Gao J, He S, Zhang Y, Wang Q. An evaluation on the efficacy and safety of treatments for attention deficit hyperactivity disorder in children and adolescents: a comparison of multiple treatments. Mol Neurobiol. 2017;54(9):6655\u201369.","journal-title":"Mol Neurobiol"},{"issue":"8","key":"249_CR15","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1185\/03007995.2014.904772","volume":"30","author":"NS Roskell","year":"2014","unstructured":"Roskell NS, Setyawan J, Zimovetz EA, Hodgkins P. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine. Curr Med Res Opin. 2014;30(8):1673\u201385.","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"249_CR16","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1097\/CHI.0b013e3181b26e9f","volume":"48","author":"MH Bloch","year":"2009","unstructured":"Bloch MH, Panza KE, Landeros-Weisenberger A, Leckman JF. Meta-analysis: treatment of attention-deficit\/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry. 2009;48(9):884\u201393.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"249_CR17","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00213-007-0840-x","volume":"194","author":"JYW Cheng","year":"2007","unstructured":"Cheng JYW, Chen RYL, Ko JSN, Ng EML. Efficacy and safety of atomoxetine for attention-deficit\/hyperactivity disorder in children and adolescents\u2014meta-analysis and meta-regression analysis. Psychopharmacology. 2007;194:197\u2013209.","journal-title":"Psychopharmacology"},{"issue":"4","key":"249_CR18","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/aur.2059","volume":"12","author":"S Patra","year":"2019","unstructured":"Patra S, Nebhinani N, Viswanathan A, Kirubakaran R. Atomoxetine for attention deficit hyperactivity disorder in children and adolescents with autism: a systematic review and meta-analysis. Autism Res. 2019;12(4):542\u201352.","journal-title":"Autism Res"},{"issue":"10","key":"249_CR19","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1007\/s10803-013-1793-z","volume":"43","author":"B Reichow","year":"2013","unstructured":"Reichow B, Volkmar FR, Bloch MH. Systematic review and meta-analysis of pharmacological treatment of the symptoms of attention-deficit\/hyperactivity disorder in children with pervasive developmental disorders. J Autism Dev Disord. 2013;43(10):2435\u201341.","journal-title":"J Autism Dev Disord"},{"issue":"2","key":"249_CR20","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jaac.2013.11.005","volume":"53","author":"S Schwartz","year":"2014","unstructured":"Schwartz S, Correll CU. Efficacy and safety of atomoxetine in children and adolescents with attention-deficit\/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression. J Am Acad Child Adolesc Psychiatry. 2014;53(2):174\u201387.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"4","key":"249_CR21","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1177\/1087054710389989","volume":"16","author":"GW van Wyk","year":"2012","unstructured":"van Wyk GW, Hazell PL, Kohn MR, Granger RE, Walton RJ. How oppositionality, inattention, and hyperactivity affect response to atomoxetine versus methylphenidate: a pooled meta-analysis. J Atten Disord. 2012;16(4):314\u201324.","journal-title":"J Atten Disord"},{"issue":"2","key":"249_CR22","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/YIC.0000000000000243","volume":"34","author":"CB Villas-Boas","year":"2019","unstructured":"Villas-Boas CB, Chierrito D, Fernandez-Llimos F, Tonin FS, Sanches ACC. Pharmacological treatment of attention-deficit hyperactivity disorder comorbid with an anxiety disorder: a systematic review. Int Clin Psychopharmacol. 2019;34(2):57\u201364.","journal-title":"Int Clin Psychopharmacol"},{"issue":"5","key":"249_CR23","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1177\/2045125316647686","volume":"6","author":"SL Hutchison","year":"2016","unstructured":"Hutchison SL, Ghuman JK, Ghuman HS, Karpov I, Schuster JM. Efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in patients with common comorbidities in children, adolescents and adults: a review. Ther Adv Psychopharmacol. 2016;6(5):317\u201334.","journal-title":"Ther Adv Psychopharmacol"},{"issue":"9","key":"249_CR24","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1097\/01.CHI.0000070245.24125.B6","volume":"42","author":"BR Collett","year":"2003","unstructured":"Collett BR, Ohan JL, Myers KM. Ten-year review of rating scales. V: scales assessing attention-deficit\/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2003;42(9):1015\u201337.","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"issue":"4","key":"249_CR25","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/mpr.7","volume":"14","author":"S Zhang","year":"2005","unstructured":"Zhang S, Faries DE, Vowles M, Michelson D. ADHD Rating Scale IV: psychometric properties from a multinational study as a clinician-administered instrument. Int J Methods Psychiatr Res. 2005;14(4):186\u2013201.","journal-title":"Int J Methods Psychiatr Res"},{"key":"249_CR26","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"issue":"7","key":"249_CR27","doi-asserted-by":"publisher","first-page":"e010919","DOI":"10.1136\/bmjopen-2015-010919","volume":"6","author":"TA Furukawa","year":"2016","unstructured":"Furukawa TA, Salanti G, Atkinson LZ, et al. Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis. BMJ Open. 2016;6(7):e010919.","journal-title":"BMJ Open"},{"issue":"12","key":"249_CR28","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1212\/01.wnl.0000188869.58300.a7","volume":"65","author":"AJ Allen","year":"2005","unstructured":"Allen AJ, Kurlan RM, Gilbert DL, et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology. 2005;65(12):1941\u20139.","journal-title":"Neurology"},{"issue":"4","key":"249_CR29","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1089\/cap.2007.0066","volume":"17","author":"ME Bangs","year":"2007","unstructured":"Bangs ME, Emslie GJ, Spencer TJ, et al. Efficacy and safety of atomoxetine in adolescents with attention-deficit\/hyperactivity disorder and major depression. J Child Adolesc Psychopharmacol. 2007;17(4):407\u201319.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"249_CR30","doi-asserted-by":"publisher","first-page":"e314","DOI":"10.1542\/peds.2006-1880","volume":"121","author":"ME Bangs","year":"2008","unstructured":"Bangs ME, Hazell P, Danckaerts M, et al. Atomoxetine for the treatment of attention-deficit\/hyperactivity disorder and oppositional defiant disorder. Pediatrics. 2008;121:e314\u201320.","journal-title":"Pediatrics"},{"issue":"9","key":"249_CR31","first-page":"755","volume":"24","author":"DF Connor","year":"2010","unstructured":"Connor DF, Findling RL, Kollins SH, et al. Effects of guanfacine extended release on oppositional symptoms in children aged 6\u201312 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. CNS Drugs. 2010;24(9):755\u201368.","journal-title":"CNS Drugs"},{"issue":"11","key":"249_CR32","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.euroneuro.2009.07.008","volume":"19","author":"G Dell'Agnello","year":"2009","unstructured":"Dell\u2019Agnello G, Maschietto D, Bravaccio C, et al. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit\/hyperactivity disorder and comorbid oppositional defiant disorder: a placebo-controlled Italian study. Eur Neuropsychopharmacol. 2009;19(11):822\u201334.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"249_CR33","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1089\/cap.2009.0111","volume":"21","author":"RW Dittmann","year":"2011","unstructured":"Dittmann RW, Schacht A, Helsberg K, et al. Atomoxetine versus placebo in children and adolescents with attention-deficit\/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany. J Child Adolesc Psychopharmacol. 2011;21(2):97\u2013110.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"9","key":"249_CR34","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1097\/chi.0b013e3180ca8385","volume":"46","author":"D Geller","year":"2007","unstructured":"Geller D, Donnelly C, Lopez F, et al. Atomoxetine treatment for pediatric patients with attention-deficit\/hyperactivity disorder with comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(9):1119\u201327.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"249_CR35","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jpsychires.2018.03.009","volume":"102","author":"KR Griffiths","year":"2018","unstructured":"Griffiths KR, Leikauf JE, Tsang TW, et al. Response inhibition and emotional cognition improved by atomoxetine in children and adolescents with ADHD: the ACTION randomized controlled trial. J Psychiatr Res. 2018;102:57\u201364.","journal-title":"J Psychiatr Res"},{"issue":"11","key":"249_CR36","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.jaac.2015.08.013","volume":"54","author":"BL Handen","year":"2015","unstructured":"Handen BL, Aman MG, Arnold LE, et al. Atomoxetine, parent training, and their combination in children with autism spectrum disorder and attention-deficit\/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2015;54(11):905\u201315.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"4","key":"249_CR37","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/DBP.0b013e3181739b9d","volume":"29","author":"BL Handen","year":"2008","unstructured":"Handen BL, Sahl R, Hardan AY. Guanfacine in children with autism and\/or intellectual disabilities. J Dev Behav Pediatr. 2008;29(4):303\u20138.","journal-title":"J Dev Behav Pediatr"},{"issue":"7","key":"249_CR38","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.jaac.2012.04.011","volume":"51","author":"M Harfterkamp","year":"2012","unstructured":"Harfterkamp M, van de Loo-Neus G, Minderaa RB, et al. A randomized double-blind study of atomoxetine versus placebo for attention-deficit\/hyperactivity disorder symptoms in children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry. 2012;51(7):733\u201341.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"249_CR39","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1177\/108705470400800202","volume":"8","author":"S Kaplan","year":"2004","unstructured":"Kaplan S, Heiligenstein J, West S, et al. Efficacy and safety of atomoxetine in childhood attention-deficit\/hyperactivity disorder with comorbid oppositional defiant disorder. J Atten Disord. 2004;8(2):45\u201352.","journal-title":"J Atten Disord"},{"issue":"4","key":"249_CR40","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1212\/WNL.58.4.527","volume":"58","author":"Tourette's Syndrome Study Group","year":"2002","unstructured":"Tourette\u2019s Syndrome Study Group. Treatment of ADHD in children with tics: A randomized controlled trial. Neurology. 2002;58(4):527\u201336.","journal-title":"Neurology"},{"key":"249_CR41","unstructured":"NCT00498173. Effectiveness of atomoxetine in treating ADHD symptoms in children and adolescents with autism. 2017. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00498173. Accessed 4 Mar 2020."},{"issue":"3","key":"249_CR42","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/00004583-200503000-00008","volume":"44","author":"JH Newcorn","year":"2005","unstructured":"Newcorn JH, Spencer TJ, Biederman J, Milton DR, Michelson D. Atomoxetine treatment in children and adolescents with attention-deficit\/hyperactivity disorder and comorbid oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry. 2005;44(3):240\u20138.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"249_CR43","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/cap.2012.0096","volume":"23","author":"DA Pearson","year":"2013","unstructured":"Pearson DA, Santos CW, Aman MG, et al. Effects of extended release methylphenidate treatment on ratings of attention-deficit\/hyperactivity disorder (ADHD) and associated behavior in children with autism spectrum disorders and ADHD symptoms. J Child Adolesc Psychopharmacol. 2013;23(5):337\u201351.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"7","key":"249_CR44","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1176\/appi.ajp.158.7.1067","volume":"158","author":"L Scahill","year":"2001","unstructured":"Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry. 2001;158(7):1067\u201374.","journal-title":"Am J Psychiatry"},{"issue":"12","key":"249_CR45","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1176\/appi.ajp.2015.15010055","volume":"172","author":"L Scahill","year":"2015","unstructured":"Scahill L, McCracken JT, King BH, et al. Extended-release guanfacine for hyperactivity in children with autism spectrum disorder. Am J Psychiatry. 2015;172(12):1197\u2013206.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"249_CR46","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.clinthera.2006.03.006","volume":"28","author":"TJ Spencer","year":"2006","unstructured":"Spencer TJ, Abikoff HB, Connor DF, et al. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit\/hyperactivity disorder in school-aged children and adolescents: a 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced\u2013dose-escalation study. Clin Ther. 2006;28(3):402\u201318.","journal-title":"Clin Ther"},{"key":"249_CR47","first-page":"195","volume":"17","author":"O Abali","year":"2007","unstructured":"Abali O, Mukaddes NM. Methylphenidate induced hallucinations: case report. Klinik Psikofarmakoloji B\u00fclteni. 2007;17:195\u20137.","journal-title":"Klinik Psikofarmakoloji B\u00fclteni"},{"issue":"5","key":"249_CR48","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1097\/01.chi.0000155320.52322.37","volume":"44","author":"H Abikoff","year":"2005","unstructured":"Abikoff H, McGough J, Vitiello B, et al. Sequential pharmacotherapy for children with comorbid attention-deficit\/hyperactivity and anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2005;44(5):418\u201327.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"Suppl 1","key":"249_CR49","first-page":"53","volume":"18","author":"E Aktepe","year":"2017","unstructured":"Aktepe E, Erdo\u011fan Y. Methylphenidate-induced visual hallucinations in a child with autism spectrum disorder and ADHD: a case report. Anadolu Psikiyatri Derg. 2017;18(Suppl 1):53\u20135.","journal-title":"Anadolu Psikiyatri Derg"},{"issue":"10","key":"249_CR50","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1097\/01.chi.0000231976.28719.2a","volume":"45","author":"LE Arnold","year":"2006","unstructured":"Arnold LE, Aman MG, Cook AM, et al. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry. 2006;45(10):1196\u2013205.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"3","key":"249_CR51","doi-asserted-by":"publisher","first-page":"177","DOI":"10.5472\/MMJcr.2903.01","volume":"29","author":"E Atabay","year":"2016","unstructured":"Atabay E, Rodopman AA. Hallusinosis due to methylphenidate overdose in an eight-year-old child: a case report. Marmara Med J. 2016;29(3):177\u201380.","journal-title":"Marmara Med J"},{"issue":"5","key":"249_CR52","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/00004583-199705000-00008","volume":"36","author":"FX Castellanos","year":"1997","unstructured":"Castellanos FX, Giedd JN, Elia J, et al. Controlled stimulant treatment of ADHD and comorbid Tourette\u2019s syndrome: effects of stimulant and dose. J Am Acad Child Adolesc Psychiatry. 1997;36(5):589\u201396.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"9","key":"249_CR53","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1097\/00004583-199509000-00010","volume":"34","author":"PB Chappell","year":"1995","unstructured":"Chappell PB, Riddle MA, Scahill L, et al. Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette\u2019s syndrome: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry. 1995;34(9):1140\u20136.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"8","key":"249_CR54","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1177\/1087054710376907","volume":"15","author":"C Charnsil","year":"2011","unstructured":"Charnsil C. Efficacy of atomoxetine in children with severe autistic disorders and symptoms of ADHD: an open-label study. J Atten Disord. 2011;15(8):684\u20139.","journal-title":"J Atten Disord"},{"key":"249_CR55","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/000992280003900102","volume":"39","author":"DF Connor","year":"2000","unstructured":"Connor DF, Barkley RA, Davis HT. A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. Clin Pediatr. 2000;39:15\u201325.","journal-title":"Clin Pediatr"},{"issue":"4","key":"249_CR56","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/00004583-199904000-00012","volume":"38","author":"IR Diamond","year":"1999","unstructured":"Diamond IR, Tannock R, Schachar RJ. Response to methylphenidate in children with ADHD and comorbid anxiety. J Am Acad Child Adolesc Psychiatry. 1999;38(4):402\u20139.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"249_CR57","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1097\/PEC.0b013e31829ec525","volume":"29","author":"DM Fein","year":"2013","unstructured":"Fein DM, Hafeez ZF, Cavagnaro C. An overdose of extended-release guanfacine. Pediatr Emerg Care. 2013;29:929\u201331.","journal-title":"Pediatr Emerg Care"},{"issue":"6","key":"249_CR58","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1177\/1087054711423626","volume":"17","author":"A Fern\u00e1ndez-Ja\u00e9n","year":"2013","unstructured":"Fern\u00e1ndez-Ja\u00e9n A, Fern\u00e1ndez-Mayoralas DM, Calleja-P\u00e9rez B, Mu\u00f1oz-Jare\u00f1o N, Campos D\u00edaz MR, L\u00f3pez-Arribas S. Efficacy of atomoxetine for the treatment of ADHD symptoms in patients with pervasive developmental disorders: a prospective, open-label study. J Atten Disord. 2013;17(6):497\u2013505.","journal-title":"J Atten Disord"},{"issue":"3","key":"249_CR59","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1089\/cap.1996.6.165","volume":"6","author":"RL Findling","year":"1996","unstructured":"Findling RL. Open-label treatment of comorbid depression and attentional disorders with co-administration of serotonin reuptake inhibitors and psychostimulants in children, adolescents, and adults: a case series. J Child Adolesc Psychopharmacol. 1996;6(3):165\u201375.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"3","key":"249_CR60","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1177\/1087054709356405","volume":"15","author":"KD Gadow","year":"2011","unstructured":"Gadow KD, Nolan EE. Methylphenidate and comorbid anxiety disorder in children with both chronic multiple tic disorder and ADHD. J Atten Disord. 2011;15(3):246\u201356.","journal-title":"J Atten Disord"},{"issue":"7","key":"249_CR61","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1097\/chi.0b013e31805c0860","volume":"46","author":"KD Gadow","year":"2007","unstructured":"Gadow KD, Sverd J, Nolan EE, Sprafkin J, Schneider J. Immediate-release methylphenidate for ADHD in children with comorbid chronic multiple tic disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):840\u20138.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"4","key":"249_CR62","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1001\/archpsyc.56.4.330","volume":"56","author":"KD Gadow","year":"1999","unstructured":"Gadow KD, Sverd J, Sprafkin J, Nolan EE, Grossman S. Long-term methylphenidate therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Arch Gen Psychiatry. 1999;56(4):330\u20136.","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"249_CR63","doi-asserted-by":"publisher","first-page":"114","DOI":"10.4103\/2229-516X.157162","volume":"5","author":"J Garg","year":"2015","unstructured":"Garg J, Arun P, Chavan BS. Comparative efficacy of methylphenidate and atomoxetine in oppositional defiant disorder comorbid with attention deficit hyperactivity disorder. Int J Appl Basic Med Res. 2015;5(2):114\u20138.","journal-title":"Int J Appl Basic Med Res"},{"issue":"5","key":"249_CR64","first-page":"101","volume":"32","author":"M Goetz","year":"2011","unstructured":"Goetz M, P\u0159\u00edhodov\u00e1 I, Hrdli\u010dka M. Long lasting complex nocturnal hallucinations during osmotic release oral system (OROS) methylphenidate treatment in a 7-year old girl. Neuro Endocrinol Lett. 2011;32(5):101\u20134.","journal-title":"Neuro Endocrinol Lett"},{"issue":"8","key":"249_CR65","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1089\/cap.2019.0025","volume":"29","author":"ZN G\u00fclle","year":"2019","unstructured":"G\u00fclle ZN, Karayagmurlu A, Coskun M. Raynaud\u2019s phenomenon related with atomoxetine treatment in a child with autism and attention-deficit\/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2019;29(8):649\u201350.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"3","key":"249_CR66","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1023\/A:1005548619694","volume":"30","author":"BL Handen","year":"2000","unstructured":"Handen BL, Johnson CR, Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord. 2000;30(3):245\u201355.","journal-title":"J Autism Dev Disord"},{"issue":"3","key":"249_CR67","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1089\/cap.2012.0012","volume":"23","author":"M Harfterkamp","year":"2013","unstructured":"Harfterkamp M, Buitelaar JK, Minderaa RB, van de Loo-Neus G, van der Gaag RJ, Hoekstra PJ. Long-term treatment with atomoxetine for attention-deficit\/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study. J Child Adolesc Psychopharmacol. 2013;23(3):194\u20139.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"249_CR68","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.psychres.2016.12.010","volume":"251","author":"L Jahangard","year":"2017","unstructured":"Jahangard L, Akbarian S, Haghighi M, et al. Children with ADHD and symptoms of oppositional defiant disorder improved in behavior when treated with methylphenidate and adjuvant risperidone, though weight gain was also observed\u2014results from a randomized, double-blind, placebo-controlled clinical trial. Psychiatry Res. 2017;251:182\u201391.","journal-title":"Psychiatry Res"},{"issue":"9","key":"249_CR69","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1089\/cap.2015.0179","volume":"26","author":"A Kilincaslan","year":"2016","unstructured":"Kilincaslan A, Mutluer TD, Pasabeyoglu B, Tutkunkardas MD, Mukaddes NM. Effects of atomoxetine in individuals with attention-deficit\/hyperactivity disorder and low-functioning autism spectrum disorder. J Child Adolesc Psychopharmacol. 2016;26(9):798\u2013806.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"8","key":"249_CR70","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1007\/s10803-017-3125-1","volume":"47","author":"SJ Kim","year":"2017","unstructured":"Kim SJ, Shonka S, French WP, Strickland J, Miller L, Stein MA. Dose-response effects of long-acting liquid methylphenidate in children with attention deficit\/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD): a pilot study. J Autism Dev Disord. 2017;47(8):2307\u201313.","journal-title":"J Autism Dev Disord"},{"issue":"5","key":"249_CR71","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1097\/00004583-199009000-00005","volume":"29","author":"R Klorman","year":"1990","unstructured":"Klorman R, Brumaghim JT, Fitzpatrick PA, Borgstedt AD. Clinical effects of a controlled trial of methylphenidate on adolescents with attention deficit disorder. J Am Acad Child Adolesc Psychiatry. 1990;29(5):702\u20139.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"249_CR72","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1097\/00004583-199905000-00020","volume":"38","author":"DJ Kolko","year":"1999","unstructured":"Kolko DJ, Bukstein OG, Barron J. Methylphenidate and behavior modification in children with ADHD and comorbid ODD or CD: main and incremental effects across settings. J Am Acad Child Adolesc Psychiatry. 1999;38(5):578\u201386.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"9","key":"249_CR73","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1097\/01.chi.0000169012.81536.38","volume":"44","author":"CJ Kratochvil","year":"2005","unstructured":"Kratochvil CJ, Newcorn JH, Arnold LE, et al. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry. 2005;44(9):915\u201324.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"3","key":"249_CR74","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1089\/cap.2006.0012","volume":"17","author":"WG Kronenberger","year":"2007","unstructured":"Kronenberger WG, Giauque AL, Lafata DE, Bohnstedt BN, Maxey LE, Dunn DW. Quetiapine addition in methylphenidate treatment-resistant adolescents with comorbid attention-deficit\/hyperactivity disorder, conduct\/oppositional-defiant disorder, and aggression: a prospective, open-label study. J Child Adolesc Psychopharmacol. 2007;17(3):334\u201347.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"4","key":"249_CR75","doi-asserted-by":"publisher","first-page":"364","DOI":"10.5455\/bcp.20110429040705","volume":"21","author":"M K\u00fc\u00e7\u00fckk\u00f6se","year":"2011","unstructured":"K\u00fc\u00e7\u00fckk\u00f6se M, \u00d6zbaran NB, K\u00f6se SG. Motor tics due to atomoxetine use: a case report. Klinik Psikofarmakoloji Bulteni. 2011;21(4):364\u20137.","journal-title":"Klinik Psikofarmakoloji Bulteni"},{"issue":"8","key":"249_CR76","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1097\/00004583-199908000-00009","volume":"38","author":"SF Law","year":"1999","unstructured":"Law SF, Schachar RJ. Do typical clinical doses of methylphenidate cause tics in children treated for attention-deficit hyperactivity disorder? J Am Acad Child Adolesc Psychiatry. 1999;38(8):944\u201351.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"249_CR77","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1089\/cap.2005.15.331","volume":"15","author":"M Ledbetter","year":"2005","unstructured":"Ledbetter M. Atomoxetine use associated with onset of a motor tic. J Child Adolesc Psychopharmacol. 2005;15(2):331\u20133.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"8","key":"249_CR78","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1089\/cap.2014.0038","volume":"24","author":"CC Liu","year":"2014","unstructured":"Liu CC, Lan CC, Chen YS. Atomoxetine-induced mania with auditory hallucination in an 8-year-old boy with attention-deficit\/hyperactivity disorder and tic disorder. J Child Adolesc Psychopharmacol. 2014;24(8):466\u20137.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"5","key":"249_CR79","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1097\/JCP.0000000000000747","volume":"37","author":"G Masi","year":"2017","unstructured":"Masi G, Manfredi A, Nieri G, Muratori P, Pfanner C, Milone A. A naturalistic comparison of methylphenidate and risperidone monotherapy in drug-naive youth with attention-deficit\/hyperactivity disorder comorbid with oppositional defiant disorder and aggression. J Clin Psychopharmacol. 2017;37(5):590\u20134.","journal-title":"J Clin Psychopharmacol"},{"key":"249_CR80","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12991-019-0226-6","volume":"18","author":"K Okazaki","year":"2019","unstructured":"Okazaki K, Yamamuro K, Iida J, Kishimoto T. Guanfacine monotherapy for ADHD\/ASD comorbid with Tourette syndrome: a case report. Ann Gen Psychiatry. 2019;18:2.","journal-title":"Ann Gen Psychiatry."},{"issue":"4","key":"249_CR81","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2190\/PM.37.4.e","volume":"37","author":"HC P\u00e1rraga","year":"2007","unstructured":"P\u00e1rraga HC, P\u00e1rraga MI, Harris DK. Tic exacerbation and precipitation during atomoxetine treatment in two children with attention-deficit hyperactivity disorder. Int J Psychiatry Med. 2007;37(4):415\u201324.","journal-title":"Int J Psychiatry Med"},{"issue":"6","key":"249_CR82","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1089\/cap.2013.2362","volume":"23","author":"JD Pedraza","year":"2013","unstructured":"Pedraza JD, Coffey B. Obsessive-compulsive disorder and comorbid attention-deficit\/hyperactivity disorder: a complex diagnostic disentanglement and treatment. J Child Adolesc Psychopharmacol. 2013;23(6):419\u201322.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"5","key":"249_CR83","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1089\/cap.2006.16.599","volume":"16","author":"DJ Posey","year":"2006","unstructured":"Posey DJ, Wiegand RE, Wilkerson J, Maynard M, Stigler KA, McDougle CJ. Open-label atomoxetine for attention-deficit\/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2006;16(5):599\u2013610.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"249_CR84","doi-asserted-by":"crossref","unstructured":"Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry. 2005;62(11):1266\u201374.","DOI":"10.1001\/archpsyc.62.11.1266"},{"issue":"2","key":"249_CR85","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1177\/0269881107069466","volume":"21","author":"O Sabuncuoglu","year":"2007","unstructured":"Sabuncuoglu O. Risperidone-to-methylphenidate switch reaction in children: three cases. J Psychopharmacol. 2007;21(2):216\u20139.","journal-title":"J Psychopharmacol"},{"issue":"5","key":"249_CR86","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/j.1365-2214.2006.00631.x","volume":"32","author":"PJ Santosh","year":"2006","unstructured":"Santosh PJ, Baird G, Pityaratstian N, Tavare E, Gringras P. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study. Child Care Health Dev. 2006;32(5):575\u201383.","journal-title":"Child Care Health Dev"},{"issue":"5","key":"249_CR87","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1089\/cap.2006.16.589","volume":"16","author":"L Scahill","year":"2006","unstructured":"Scahill L, Aman MG, McDougle CJ, et al. A prospective open trial of guanfacine in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2006;16(5):589\u201398.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"9","key":"249_CR88","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1089\/cap.2013.2392","volume":"23","author":"R Sood","year":"2013","unstructured":"Sood R, Coffey BJ. Pharmacotherapeutic challenges in the management of attention-deficit\/hyperactivity disorder and chronic tics in a school aged child. J Child Adolesc Psychopharmacol. 2013;23(9):628\u201331.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"249_CR89","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/00004583-198803000-00007","volume":"27","author":"ML Speltz","year":"1988","unstructured":"Speltz ML, Varley CK, Peterson K, Beilke RL. Effects of dextroamphetamine and contingency management on a preschooler with ADHD and oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry. 1988;27(2):175\u20138.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"249_CR90","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1089\/cap.2006.16.611","volume":"16","author":"PW Troost","year":"2006","unstructured":"Troost PW, Steenhuis MP, Tuynman-Qua HG, et al. Atomoxetine for attention-deficit\/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study. J Child Adolesc Psychopharmacol. 2006;16(5):611\u20139.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"9","key":"249_CR91","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1111\/j.1651-2227.2011.02263.x","volume":"100","author":"P Zeiner","year":"2011","unstructured":"Zeiner P, Gjevik E, Weidle B. Response to atomoxetine in boys with high-functioning autism spectrum disorders and attention deficit\/hyperactivity disorder. Acta Paediatr. 2011;100(9):1258\u201361.","journal-title":"Acta Paediatr"},{"issue":"4","key":"249_CR92","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1089\/cap.2008.0137","volume":"19","author":"JK Ghuman","year":"2009","unstructured":"Ghuman JK, Aman MG, Lecavalier L, et al. Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit\/hyperactivity disorder symptoms in preschoolers with developmental disorders. J Child Adolesc Psychopharmacol. 2009;19(4):329\u201339.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"7","key":"249_CR93","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/DBP.0000000000000822","volume":"41","author":"JH Newcorn","year":"2020","unstructured":"Newcorn JH, Huss M, Connor DF, Hervas A, Werner-Kiechle T, Robertson B. Efficacy of guanfacine extended release in children and adolescents with attention-deficit\/hyperactivity disorder and comorbid oppositional defiant disorder. J Dev Behav Pediatr. 2020;41(7):565\u201370.","journal-title":"J Dev Behav Pediatr"},{"issue":"10","key":"249_CR94","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s40263-015-0266-7","volume":"29","author":"S Cortese","year":"2015","unstructured":"Cortese S, Panei P, Arcieri R, et al. Safety of methylphenidate and atomoxetine in children with attention-deficit\/hyperactivity disorder (ADHD): data from the Italian National ADHD Registry. CNS Drugs. 2015;29(10):865\u201377.","journal-title":"CNS Drugs"},{"issue":"10","key":"249_CR95","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s00787-018-1125-0","volume":"27","author":"S Padilha","year":"2018","unstructured":"Padilha S, Virtuoso S, Tonin FS, Borba HHL, Pontarolo R. Efficacy and safety of drugs for attention deficit hyperactivity disorder in children and adolescents: a network meta-analysis. Eur Child Adolesc Psychiatry. 2018;27(10):1335\u201345.","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"10","key":"249_CR96","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1007\/s00787-018-1113-4","volume":"27","author":"M Huss","year":"2018","unstructured":"Huss M, Dirks B, Gu J, Robertson B, Newcorn JH, Ramos-Quiroga JA. Long-term safety and efficacy of guanfacine extended release in children and adolescents with ADHD. Eur Child Adolesc Psychiatry. 2018;27(10):1283\u201394.","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"1","key":"249_CR97","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s40263-019-00686-4","volume":"34","author":"R Houghton","year":"2020","unstructured":"Houghton R, de Vries F, Loss G. Psychostimulants\/atomoxetine and serious cardiovascular events in children with ADHD or autism spectrum disorder. CNS Drugs. 2020;34(1):93\u2013101.","journal-title":"CNS Drugs"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-021-00249-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-021-00249-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-021-00249-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T07:17:49Z","timestamp":1725175069000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-021-00249-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,4]]},"references-count":97,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["249"],"URL":"https:\/\/doi.org\/10.1007\/s40120-021-00249-0","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,4]]},"assertion":[{"value":"9 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}